Conx Corp. (NASDAQ:CONX)

Saturday, November 20, 2010 | Web News
Fiscal year ended June 30, 2010 Adjusted EBITDA for the year was $815,981 vs. $403,741 for the prior year....
See All Research...
CORGENIX is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network.

Web site: http://www.corgenix.com

Last updated July 30, 2008


Market Data powered by QuoteMedia. Terms of Use